Delivery Order SPE2DR25D3103-SPE2DR26F9K78
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution in a 120ml quantity, with a contract ceiling value of $1,775.04. This competitively awarded, firm fixed-price delivery order is expected to be completed by December 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution in a 120 ml unit at a firm fixed price of $1,263.27. This is an unset-aside, competitively awarded delivery order with an ultimate completion date of June 25, 2025, to be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 5, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution (120ml) under a firm fixed-price contract with a ceiling value of $2,662.56. This is a competitive award with no set-aside designation, and performance is scheduled for completion by December 29, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This...
- The Defense Logistics Agency awarded a $10,106.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Hemangeol 4.28 mg/mL oral solution (120 mL) on August 29, 2025, with completion targeted for September 22, 2025. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution in 120ml quantities, with a contract ceiling value of $1,263.24 and firm fixed pricing. This competitively awarded, non-set-aside delivery order is scheduled for completion by November 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the prescription medication Hemangeol (4.28 mg/ml oral solution, 120 ml). The contract has a firm fixed price of $1,263.27 and a performance period that extends through May 23, 2025. This contract is not designated as a set-aside and is therefore open to competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- This is a $3,368.72 Firm Fixed Price Delivery Order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product, with a period of performance through March 10, 2025. This contract award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, the Corporate Office division of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The $1,656.80 firm fixed price contract is for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product. The contract has a completion date of May 8, 2024 and does not have a set-aside designation. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp, the prime contractor on this pediatric pharmaceutical supply contract valued at $14,396.30. This firm fixed-price delivery order, issued on September 4, 2025, with an ultimate completion date of September 5, 2025, represents a competitive award with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Hemlibra 105 mg/0.7 mL vials with a ceiling value of $24,673.08 under a firm fixed-price contract structure. This delivery order, which is scheduled for completion by November 17, 2025, represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The award is executed as a child contract under...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9K78Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution (120ml) with a contract value of $2,662.56 and a firm fixed price structure. The order is set to be completed by December 22, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, was selected through competitive procurement without set-aside designation to fulfill this specialized pharmaceutical requirement. The contract aligns with the company's established role as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency operations and other government healthcare systems. Hemangeol, a beta-blocker used in the treatment of infantile hemangiomas, represents the type of specialty pharmaceutical product the contractor routinely supplies across multiple therapeutic domains through its expansive federal contract portfolio with the Defense Logistics Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 11/30/25 |